GCG and type 2 diabetes mellitus: The potential of reducing glucagon secretion (e.g. using GLP-1) or inhibiting glucagon action (e.g. with glucagon receptor antagonists) have received much attention as therapeutic strategies for the treatment of excess glucose production in type 2 diabetic patients [15], [16].